Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Biotechnology

Isomorphic Labs Raises $5 Billion to Take AI Drugs to Trials

Sreepriya Prasannan
Sreepriya Prasannan

NewsWritten by our team from the primary sources linked below. Reviewed, verified and approved by a human editor. How we check

Speed:
Isomorphic Labs Raises $5 Billion to Take AI Drugs to Trials

Isomorphic Labs, the London AI drug discovery company founded by Sir Demis Hassabis, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, it announced on 17 November 2026. The money will scale its IsoDDE drug design engine and push its first therapeutic programmes towards clinical trials.

The round comes six months after a $2.1 billion Series B and brings the company's announced external funding to $7.7 billion. Alphabet, which spun Isomorphic out of DeepMind in 2021, made what the company calls a "continued significant investment". The new valuation was not disclosed.

Key Highlights:
  • Deal: a $5 billion Series C, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz (a16z) and other new investors, announced in London on 17 November 2026.
  • Existing backers: Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund all took part again.
  • Use of funds: scaling the IsoDDE drug design engine, the internal and partnered pipeline, and "AI-first translational and clinical development infrastructure".
  • Pipeline: the company reports positive preclinical results in oncology and immunology. No candidate has yet entered human trials.
  • Scale: BioPharma Dive says it is the largest of all the financings it has tracked since 2022. Valuation: not disclosed.

Who invested in the Isomorphic Labs Series C?

The company's news release says the round "was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz (a16z) and several other new investors, with continued significant investment from Alphabet." It adds that "all existing investors" took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The release describes the round as oversubscribed.

Isomorphic did not disclose its valuation. TechCrunch notes that Bloomberg reported earlier in November that the company was seeking to raise funding at a $50 billion valuation. That figure comes from Bloomberg's report on the talks, not from the company, and Priya Life Science has not been able to confirm it.

BioPharma Dive, which follows venture deals across the biotech sector, wrote that "the latest $5 billion Series C is the largest among all financings tracked since 2022." It also reported that Isomorphic's May and November rounds are the two biggest venture capital infusions of the year among the companies it tracks.

What will the $5 billion pay for?

According to the release, Isomorphic is scaling "its proprietary drug design engine IsoDDE and therapeutic candidate pipeline designed with AI". It describes IsoDDE as a suite of foundational simulation AI models that work across several therapeutic areas and drug modalities, combined with what it calls proprietary agents that "navigate and reason over highly complex biological systems".

The company lists four uses for the new capital:

  • maturing IsoDDE and expanding into new biology with more advanced models;
  • building a partner ecosystem to improve understanding of mechanistic disease biology;
  • building global infrastructure for AI-led bioengineering;
  • continuing to build "scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials."

Isomorphic says its work is "yielding positive preclinical results, both for internal programs in oncology and immunology and with partners, setting the stage for clinical entry." It has not published the underlying preclinical data, named its candidates or given a date for the first trial.

What did Demis Hassabis say?

"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," said Sir Demis Hassabis, Founder and CEO of Isomorphic Labs. "Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."

Max Jaderberg, President of Isomorphic Labs, said: "Every week we are making repeatable scientific advancements enabled by our models." Konstantine Buhler, Partner at Sequoia Capital, said: "Isomorphic Labs is building foundational technology for the future of medicine."

CNBC and TechCrunch report that Hassabis stepped back from leading Google DeepMind earlier this year and became its chairman, while staying on as chief executive of Isomorphic. He shared the 2024 Nobel Prize in Chemistry for AlphaFold, the protein structure prediction system on which Isomorphic's work builds.

How has Isomorphic's funding grown?

Isomorphic was founded in 2021 and is headquartered in London, with offices in Cambridge, Massachusetts and Lausanne, Switzerland. Its funding and partnership record, as announced by the company, is set out below.

Isomorphic Labs funding and partnerships (company announcements and BioPharma Dive)
DateEvent
7 January 2024Research collaborations with Eli Lilly ($45 million upfront) and Novartis ($37.5 million upfront); together potentially worth nearly $3 billion before royalties
18 February 2025Novartis collaboration expanded by up to three additional research programmes on the same financial terms
31 March 2025First external round: $600 million, led by Thrive Capital with GV and Alphabet
20 January 2026Cross-modality, multi-target research collaboration with Johnson & Johnson; terms not disclosed
12 May 2026$2.1 billion Series B led by Thrive Capital, with Alphabet and GV, and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund
17 November 2026$5 billion Series C co-led by Greenoaks and Sequoia Capital; valuation not disclosed

The three announced rounds add up to $7.7 billion. The Lilly collaboration covers small molecule therapeutics against several undisclosed targets, according to Isomorphic's partnerships page. The J&J deal is broader: Isomorphic says it covers small molecules, antibodies, peptides and molecular glues, as well as large molecule and biologics design.

Why does this matter for AI drug discovery?

The size of the round shows how much capital investors are prepared to put behind AI-first drug design before any clinical proof. BioPharma Dive points out that no approved medicine has yet been designed by AI. The real test for Isomorphic, as for its rivals, is how its candidates perform in people.

Large drugmakers are also moving into the field. BioPharma Dive lists Bristol Myers Squibb, Merck, Eli Lilly and Novo Nordisk among the companies that have announced AI investments or partnerships this year. Our half-year report on AI in pharma and our article on Anthropic's move into AI drug discovery track the wider trend.

Is there a European or Irish angle?

Isomorphic is a European company: it is based in London and has an office in Lausanne. The UK Sovereign AI Fund has backed both of its 2026 rounds. The release does not mention Ireland, and Isomorphic's partnership announcements do not name any Irish sites or staff.

The wider European policy link runs through Dublin. On 15 and 16 October 2026, University College Dublin and Research Ireland hosted the EU's AI in Science Summit (AIS26) as part of Ireland's Presidency of the Council of the EU. At the summit, the European Commission launched a pledging initiative for RAISE, the Resource for AI Science in Europe, which asks companies and foundations to give researchers access to AI models, computing capacity, data and training. Google DeepMind, Isomorphic's sister company within Alphabet, was among the first seven pledgers, alongside the Novo Nordisk Foundation, Nvidia, Elsevier, Sanofi, Frontiers and Mistral.

For Irish researchers and biotech companies, the practical question is access: to models, to compute and to partners able to run AI-designed molecules through laboratory and clinical testing. The Commission says RAISE will be reviewed annually, with progress presented at future summits.

Frequently asked questions

How much did Isomorphic Labs raise?

$5 billion in a Series C round, announced on 17 November 2026.

Who led the round?

Greenoaks and Sequoia Capital co-led it, with Andreessen Horowitz and other new investors. Alphabet and all existing investors also took part.

What is Isomorphic Labs valued at?

The company has not disclosed its valuation. Bloomberg reported earlier in November that it was seeking funding at a $50 billion valuation.

Does Isomorphic have drugs in clinical trials?

Not yet. It reports positive preclinical results in oncology and immunology and says the funding will help drive its first programmes towards clinical trials. It has not given a date.

Which pharma companies work with Isomorphic?

Eli Lilly, Novartis and Johnson & Johnson have announced research collaborations with the company.

Outlook

With $7.7 billion raised in external rounds since March 2025, Isomorphic now has the funding to take its own candidates into the clinic. The milestones to watch are the first trial registration, any publication of preclinical data, and news from the Lilly, Novartis and J&J collaborations. Priya Life Science will report when the first Isomorphic candidate enters human testing.

Sources

Cover image: AI-generated illustration.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Related from our data
Iscover 300 mg film-coated tablets — Clopidogrel hydrogensulfate · Irish Medicines Database
Drugs in this article: current clinical trials
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: a 60-second summary, then only the topics you choose: industry news, approvals and market access, shortages, Irish trials, careers or data, all built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · Biotechnology

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment